metastatic non-small cell lung cancer (NSCLC) research hub
5 indexed studies · 2 currently recruiting
- authorisedPhase I and Phase II (Integrated)- Other
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)
This study, called ALTAIR, is looking at new combinations of medicines for advanced or metastatic non-small cell lung cancer. It aims to find a safe and effective dose, and see how well these new treatments work.
Germany · Spain · France - recruiting
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
This study collects information from real-life lung cancer patients in Germany. It looks at how cancer is tested, treated, and how patients get on. The aim is to understand and improve care for lung cancer patients and see how different treatments affect them.
Germany - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)
This study is testing different combinations of treatments for advanced lung cancer. It's looking to see how well these new drug combinations work and if they are safe. The aim is to find better ways to treat non-small cell lung cancer that has spread.
France · Spain - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC
This early-stage study is for people with lung cancer that has spread. It's testing new ways to use a drug called Durvalumab, sometimes with other cancer medicines or chemotherapy, to see if they are safe and work well. It's for adults aged 18 and over.
Poland - not yet recruitingPHASE2
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study is testing new combinations of medicines for advanced lung cancer. It compares two new drugs with standard chemotherapy, or one new drug with standard chemotherapy, to see which works best and is safest for people with non-small cell lung cancer that has spread.
United States · Argentina · Australia